(ATOS) Atossa Genetics - Ratings and Ratios
Breast, Cancer, Screening, Diagnostics, Equipment
Description: ATOS Atossa Genetics
Atossa Genetics Inc (NASDAQ:ATOS) is a US-based company operating in the Health Care Equipment sub-industry. The companys stock is classified as common stock. To evaluate the investment potential of ATOS, we need to examine its financial health and key performance indicators.
The companys market capitalization stands at $100.30M USD, indicating a relatively small-cap stock. The absence of a P/E ratio and forward P/E ratio suggests that the company is not generating earnings, which is a common trait among companies in the early stages of development or those experiencing financial difficulties. The Return on Equity (RoE) is -42.83%, indicating significant losses relative to shareholder equity.
To further analyze ATOS, we should consider key economic drivers such as revenue growth, operating expenses, and cash flow management. A crucial KPI to monitor would be the companys burn rate and cash runway, as these metrics provide insight into the companys ability to sustain operations without generating positive cash flows from operations. Additionally, the companys research and development (R&D) pipeline and any potential catalysts, such as FDA approvals or partnerships, could significantly impact its valuation.
Given the companys negative RoE and lack of earnings, investors should focus on the companys ability to manage its cash resources and drive growth through its R&D initiatives. The stocks beta of 0.923 indicates that it is slightly less volatile than the overall market, but the average trading volume of 721,169 shares suggests sufficient liquidity. A thorough analysis of the companys quarterly tax provision and overall financial statements is necessary to understand the underlying drivers of its financial performance and identify potential areas for improvement.
ATOS Stock Overview
| Market Cap in USD | 104m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2012-11-08 |
ATOS Stock Ratings
| Growth Rating | -40.9% |
| Fundamental | 20.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -51.7% |
| Analyst Rating | 4.50 of 5 |
ATOS Dividends
Currently no dividends paidATOS Growth Ratios
| Growth Correlation 3m | -57.1% |
| Growth Correlation 12m | -65% |
| Growth Correlation 5y | -53.7% |
| CAGR 5y | -1.00% |
| CAGR/Max DD 3y | -0.01 |
| CAGR/Mean DD 3y | -0.03 |
| Sharpe Ratio 12m | -1.96 |
| Alpha | 0.11 |
| Beta | 0.841 |
| Volatility | 54.06% |
| Current Volume | 495.1k |
| Average Volume 20d | 481.1k |
| Stop Loss | 0.7 (-15.7%) |
| Signal | 1.18 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-28.7m TTM) > 0 and > 6% of Revenue (6% = -1.72m TTM) |
| FCFTA -0.33 (>2.0%) and ΔFCFTA -32.60pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -194.1% (prev 422.3k%; Δ -422.5kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.39 (>3.0%) and CFO -25.0m > Net Income -28.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 9.17 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (129.2m) change vs 12m ago 2.73% (target <= -2.0% for YES) |
| Gross Margin 100.1% (prev -44.44%; Δ 144.5pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover -38.17% (prev 0.02%; Δ -38.20pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -39.69
| (A) 0.86 = (Total Current Assets 62.5m - Total Current Liabilities 6.82m) / Total Assets 64.5m |
| (B) -3.52 = Retained Earnings (Balance) -226.9m / Total Assets 64.5m |
| warn (B) unusual magnitude: -3.52 — check mapping/units |
| (C) -0.38 = EBIT TTM -28.7m / Avg Total Assets 75.2m |
| (D) -29.83 = Book Value of Equity -203.4m / Total Liabilities 6.82m |
| Total Rating: -39.69 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 20.41
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -39.56% = -5.0 |
| 3. FCF Margin -73.34% = -7.50 |
| 4. Debt/Equity 0.12 = 2.49 |
| 5. Debt/Ebitda -0.24 = -2.50 |
| 6. ROIC - WACC (= -51.91)% = -12.50 |
| 7. RoE -42.83% = -2.50 |
| 8. Rev. Trend 3.99% = 0.30 |
| 9. EPS Trend 12.37% = 0.62 |
What is the price of ATOS shares?
Over the past week, the price has changed by +3.97%, over one month by +5.08%, over three months by +2.42% and over the past year by -42.75%.
Is Atossa Genetics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ATOS is around 0.70 USD . This means that ATOS is currently overvalued and has a potential downside of -15.66%.
Is ATOS a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ATOS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.6 | 578.3% |
| Analysts Target Price | 5.6 | 578.3% |
| ValueRay Target Price | 0.8 | -6% |
Last update: 2025-09-10 04:32
ATOS Fundamental Data Overview
CCE Cash And Equivalents = 57.9m USD (Cash And Short Term Investments, last quarter)
Revenue TTM is 0, using Net Income TTM -28.7m + Cost of Revenue 16.0k = -28.7m USD
P/B = 1.8091
Beta = 1.103
Revenue TTM = -28.7m USD
EBIT TTM = -28.7m USD
EBITDA TTM = -28.7m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 6.82m USD (from totalCurrentLiabilities, last quarter)
Debt = 6.82m USD (Calculated: Short Term 6.82m + Long Term 0.0)
Net Debt = -57.9m USD (from netDebt column, last quarter)
Enterprise Value = 53.2m USD (104.2m + Debt 6.82m - CCE 57.9m)
Interest Coverage Ratio = unknown (Ebit TTM -28.7m / Interest Expense TTM 0.0)
FCF Yield = -39.56% (FCF TTM -21.0m / Enterprise Value 53.2m)
FCF Margin = -73.34% (FCF TTM -21.0m / Revenue TTM -28.7m)
Net Margin = -100.1% (Net Income TTM -28.7m / Revenue TTM -28.7m)
Gross Margin = -100.1% ((Revenue TTM -28.7m - Cost of Revenue TTM 16.0k) / Revenue TTM)
Tobins Q-Ratio = -0.26 (set to none) (Enterprise Value 53.2m / Book Value Of Equity -203.4m)
Interest Expense / Debt = 12.02% (Interest Expense 820.0k / Debt 6.82m)
Taxrate = 21.0% (US default)
NOPAT = -28.7m (EBIT -28.7m, no tax applied on loss)
Current Ratio = 9.17 (Total Current Assets 62.5m / Total Current Liabilities 6.82m)
Debt / Equity = 0.12 (Debt 6.82m / last Quarter total Stockholder Equity 57.7m)
Debt / EBITDA = -0.24 (Net Debt -57.9m / EBITDA -28.7m)
Debt / FCF = -0.32 (Debt 6.82m / FCF TTM -21.0m)
Total Stockholder Equity = 67.0m (last 4 quarters mean)
RoA = -44.51% (Net Income -28.7m, Total Assets 64.5m )
RoE = -42.83% (Net Income TTM -28.7m / Total Stockholder Equity 67.0m)
RoCE = -42.77% (Ebit -28.7m / (Equity 67.0m + L.T.Debt 0.0))
RoIC = -42.77% (NOPAT -28.7m / Invested Capital 67.0m)
WACC = 9.13% (E(104.2m)/V(111.1m) * Re(9.11%)) + (D(6.82m)/V(111.1m) * Rd(12.02%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 1.55 | Cagr: 0.18%
Discount Rate = 9.11% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -21.0m)
EPS Correlation: 12.37 | EPS CAGR: -11.38% | SUE: -0.52 | # QB: 0
Revenue Correlation: 3.99 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
Additional Sources for ATOS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle